Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Linerixibat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 known ✓ | Q12908 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linerixibat SCHEMBL2579144 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| Linerixibat SCHEMBL2586025 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| Linerixibat SCHEMBL29429786 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL26226892 | 0.97 | SLC10A2 (0.94) | SLC10A2 | |
| SCHEMBL22360124 | 0.97 | SLC10A2 (0.94) | SLC10A2 | |
| SCHEMBL2591812 | 0.97 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL2590845 | 0.95 | SLC10A2 (0.90) | SLC10A2 | |
| SCHEMBL2592666 | 0.95 | SLC10A2 (0.90) | SLC10A2 | |
| SCHEMBL2590143 | 0.95 | SLC10A2 (0.90) | SLC10A2 | |
| SCHEMBL12176709 | 0.94 | SLC10A2 (1.00) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563122-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| EP-2563122-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9040518-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040518-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2563122-A1 | CHEMICAL COMPOUNDS | Glaxosmithkline LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130029938-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029938-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011137135-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011137135-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029938-A1 | Chemical Compounds | CYP11B1, GOT2, CYP11B2 | SLC10A2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.